# Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

> **NCT01748149** · EARLY_PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 40 (actual)

## Conditions studied

- Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas

## Interventions

- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01748149
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-29
- **Primary completion:** 2018-12-05
- **Final completion:** 2025-07-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01748149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01748149, "Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01748149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*